Sensei Biotherapeutics reports FY2022 net loss of $48.6M; cash runway into H2 2025

Sensei Biotherapeutics, Inc.

Net loss $48.6M vs $36.8M in 2021; loss per share $1.58.
Cash and securities $107.1M at Dec 31, 2022, down from $147.6M.
IND submitted for lead candidate SNS-101 (VISTA-blocking antibody) in March 2023.
New collaborations with Regeneron, NCI, and WashU to support SNS-101 development.
Expects to select candidates for SNS-102 and SNS-103 in 2023; cash runway into H2 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sensei Biotherapeutics, Inc. reported financial results for the full year ended December 31, 2022.

Period: the full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 28, 2023, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-081485

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.